MADRIGAL PHARMACEUTICALS, INC. 4

CMO David Soergel sold 1,042 shares of Madrigal Pharmaceuticals common stock at about $495.74 per share under a Rule 10b5-1 plan.

On June 1, 2026, Madrigal Pharmaceuticals, Inc. Chief Medical Officer David Soergel sold 1,042 shares of the company’s common stock at an average price of approximately $495.74 per share, for total proceeds of about $516,000. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 2, 2026, and was reported as a disposition of directly owned shares. Following this sale, Soergel continued to hold 10,033 shares of Madrigal common stock directly, representing a remaining stake valued at roughly $5.0 million based on the reported sale price.

Filing Facts

CIK

1157601

Ticker

MDGL

Form

4

Source Type

sec

Accession

0001628280-26-039653

Alert Tier

6